Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 547-567
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.547
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.547
Ref. | Number of patients and cohort | Results | Conclusions benefit-yes/no |
Rosenstock et al[136], 1985, Retrospective Review | 248 chronic UC patients | In this cohort of patients: Overall incidence of HGD was 6%; HGD or carcinoma found in 24 procedures in 16 patients, mean disease duration of 16 yr, 15 patients had HGD; DALM most consistent indicator of carcinoma. > 95% of cancers 6 recognized at colonoscopy | The presence/absence of dysplasia a reliable histological marker that correlates with the presence/absence of cancer in UC. DALM with HGD had the strongest indication for surgery. Benefit- yes |
Lashner et al[137], 1990, Prospective surveillance programme | 99 patients with pancolitis | In this cohort of patients: Both groups comparable in terms of age at onset, disease duration and gender; Total 8 fewer deaths in the surveillance group (P < 0.05); Colectomy was less common and was performed 4 yr later in the surveillance group (P < 0.05) | Screening in UC associated with improved survival and delayed colectomy. Findings did not show improvement in cancer-related survival. Benefit-equivocal |
Löfberg et al[138], 1990, 15-yr Prospective surveillance programme | 72 UC, 12 patients developed definite dysplasia | In this cohort of patients: LGD detected in 7 patients; HGD in 4 and 1 Dukes' Stage-A cancer at operation; The cumulative risk of developing at least LGD was 14% after 25 yr of disease; Abnormal, aneuploid DNA content detected in biopsies of 12/59 patients (20.3%) this correlated significantly with LGD and HGD | Long-term use of surveillance in UC is reliable in detecting dysplasia and identify patients for prophylactic surgery. Benefit-yes; Earlier detection of neoplasia |
Nugent et al[139], 1991, 13-yr Prospective surveillance programme | 213 UC patients | In this cohort of patients: A total of 15 patients underwent colectomy; A total of 7 patients had unsuspected carcinoma at various stages; Dysplasia detected among 11 patients; No difference in the prevalence of dysplasia between left-sided v/s extensive disease; No carcinoma detected among 175 patients without dysplasia on initial biopsies | Surveillance programme effective aid in reducing the risk of carcinoma in UC. Short term risk of CRC low if biopsy negative. Colectomy deferred in this group. Benefit-yes |
Lynch et al[140], 1993, Prospective surveillance(between 1978 and 1990) | 160 UC patients | In this cohort of patients: A total of 739 colonoscopies carried out (4.6 colonoscopies/per patient); A 709 patient-years follow-up was carried out; In 1 patient Dukes's A cancer was detected; IBD-CRC caused the death of 1 patient; Overall, 9 IBD-CRC cases were diagnosed during the study period but only 1 case was detected by way of the surveillance programme | Results of this large study with long follow-up cast doubts on the effectiveness of the surveillance programmes in detecting CRC in patients with UC. Benefit-no |
Jonsson et al[141], 1994, Prospective, longitudinal study between 1977 and 1991 | 131 patients with UC | In this cohort of patients: A total of 632 colonoscopies performed, dysplasia was diagnosed in 24 (4 HGD), other than those with cancer; CRC diagnosed in 4 patients, of whom 2 included in the programme with a diagnosis of cancer; CRC and dysplasia are seen mainly in the left colon and in pancolitis patients | The surveillance programme was resource consuming and the cost-benefit must be questioned. Benefit-no. No cost-benefit as per authors |
Karlén et al[142], 1998, Prospective case-control study | 4664 patients with UC, 142 patients with definite UC | In this cohort of patients: In 2 out of 40 patients with UC and 18/102 controls had at least one-surveillance colonoscopy (RR 0.29, 95% CI: 0.06-1.31); Out of 12 controls, only one patient with UC had two or more surveillance colonoscopies (RR 0.22, 95%CI: 0.03-1.74), indicating a protective dose-response relation | Surveillance may be associated with decreased risk of death from CRC in patients with long-standing UC. Benefit-yes. May improve survival |
Friedman et al[143], 2001, Prospective Longitudinal study | 259 patients with chronic Crohn's colitis | In this cohort of patients: A total of 663 examinations were performed on 259 patients; The median interval between examinations was 24 mo; More frequent examinations were carried out(1-6 mo) in patients with dysplasia; Dysplasia or cancer was detected in 16% (10 indefinite, 23 LGD, 4 HGD and 5 cancers); Definite dysplasia or cancer was associated with age > 45 yr and had increased symptoms | Colonoscopic surveillance should be strongly considered in chronic extensive Crohn's colitis. Benefit-yes. May improve survival |
Biasco et al[144], 2002, Prospective Longitudinal study (20 yr duration) | 65 patients with UC > 7 yr | In this cohort of patients: A total of 23 (35.3%) patients had surgery; A total of 29 (44.66%) patients discontinued the programme; Only 11 (16.9%) patients have remained in the programme | Results cast some doubts on the significance of such a programme and on its long-term feasibility. Benefit-no. Long-term feasibility doubtful |
Hata et al[145] 2003, Retrospective January 1979 and December 2001 | 217 UC patients | In this cohort of patients: A total of 15 patients were detected to have definite dysplasia; Among 5/15 proved to have invasive cancer in resected specimens; cumulative risk for development of definite dysplasia at 10, 20 and 30 yr was 3.1%, 10.0%, and 15.6% respectively; A cumulative risk for the development of invasive cancer at 10, 20, and 30 yr was 0.5%, 4.1%, and 6.1%, respectively | The surveillance programme is useful for detecting IBD-CRC and survival may be improved by surveillance colonoscopy. Benefit-yes. May improve survival |
- Citation: Majumder S, Shivaji UN, Kasturi R, Sigamani A, Ghosh S, Iacucci M. Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives. World J Gastrointest Oncol 2022; 14(3): 547-567
- URL: https://www.wjgnet.com/1948-5204/full/v14/i3/547.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i3.547